HIP2101 / Hanmi - LARVOL DELTA

Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study. (PubMed, Gut Liver) - P3 | "Therefore, this study compared the efficacy and safety of HIP2101 and 20-mg famotidine (RLD2101) in patients with gastric erosions. The efficacy and safety of HIP2101 were comparable to those of RLD2101 in the treatment of gastric erosions and symptomatic improvement. These findings suggest that HIP2101 may be a novel treatment option for gastritis (ClinicalTrials.gov identifier: NCT05024721)."

Clinical • Journal • P3 data • Gastrointestinal Disorder

Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis (clinicaltrials.gov) - P3 | N=326 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed

Trial completion • Gastrointestinal Disorder

Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis (clinicaltrials.gov) - P3; N=326; Recruiting; Sponsor: Hanmi Pharmaceutical Company Limited

Clinical • New P3 trial • Gastrointestinal Disorder